Oxular
Company

Oxular

Biotechnology Oxford, Oxfordshire, United Kingdom 4 employees
Employees
4
Contacts
3
Emails
3
Phones
1

Oxular Overview

Headquarters
Oxford, Oxfordshire, United Kingdom
Website
www.oxular.com
Industry
Biotechnology
Employees
4
Funding
37.0M

About Oxular

Oxular was acquired by Regeneron in January 2025. To continue following for updated information, please visit Regeneron’s LinkedIn. www.linkedin.com/company/regeneron-pharmaceuticals/ “One treatment a year. Life changing.” Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.

Oxular Contact Details

People in AeroLeads
4
With contact data
3
Email contacts
3
75.0% coverage
Phone contacts
1
25.0% coverage

Oxular Org Chart

Sample employees and titles
Name Title Contact
Ian Undefined Chief Technology Officer at Oxular
View
Ron Yamamoto Chief Scientific Officer at Medterials
Email Phone
Paul Pritchard Supply Chain Mgt
Email
Paul Hawkins Director of Information
Email

Employees by Management Level

Executive 2 profiles
Director 1 profile
Individual contributor 1 profile

Compare Similar Companies to Oxular